Zevra Therapeutics Inc.
$ 8.66
-0.69%
04 Dec - close price
- Market Cap 487,537,000 USD
- Current Price $ 8.66
- High / Low $ 8.80 / 8.47
- Stock P/E 18.43
- Book Value 2.37
- EPS 0.47
- Next Earning Report 2026-03-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.08 %
- ROE 0.35 %
- 52 Week High 13.16
- 52 Week Low 6.19
About
Zevra Therapeutics, Inc. is a pioneering biopharmaceutical company headquartered in Celebration, Florida, dedicated to addressing unmet medical needs in rare diseases through its advanced prodrug development platform. The company focuses on developing innovative therapies for serious conditions, leveraging proprietary technology to improve drug efficacy and enhance patient outcomes. With a robust pipeline and a strategic commitment to rare disease therapeutics, Zevra Therapeutics is well-positioned to make a meaningful impact on the healthcare landscape and deliver significant value to stakeholders.
Analyst Target Price
$22.54
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-12 | 2025-05-05 | 2025-03-26 | 2024-11-12 | 2024-08-13 | 2024-05-08 | 2024-03-05 | 2023-11-07 | 2023-08-14 | 2023-05-15 | 2023-03-07 |
| Reported EPS | -0.01 | -0.06 | -0.06 | -0.69 | -0.69 | -0.48 | -0.4 | -0.4 | -0.4 | -0.15 | -0.34 | -0.26 |
| Estimated EPS | -0.0332 | 2.19 | -0.1814 | -0.3986 | -0.42 | -0.43 | -0.48 | -0.27 | -0.3 | -0.34 | -0.23 | -0.17 |
| Surprise | 0.0232 | -2.25 | 0.1214 | -0.2914 | -0.27 | -0.05 | 0.08 | -0.13 | -0.1 | 0.19 | -0.11 | -0.09 |
| Surprise Percentage | 69.8795% | -102.7397% | 66.9239% | -73.1059% | -64.2857% | -11.6279% | 16.6667% | -48.1481% | -33.3333% | 55.8824% | -47.8261% | -52.9412% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-11 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.0238 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZVRA
2025-10-29 07:30:00
Zevra Therapeutics announced that its executive leadership team will participate in a fireside discussion at Guggenheim's 2nd Annual Healthcare Innovation Conference on November 12, 2025. Management will also be available for one-on-one meetings with registered conference attendees. A live webcast of the discussion will be accessible on the Investor Relations section of Zevra's website.
2025-10-29 07:30:00
Zevra Therapeutics announced that its executive leadership will participate in a fireside discussion at Guggenheim's 2nd Annual Healthcare Innovation Conference in Boston on November 12, 2025, at 11:30 a.m. ET. Management will also hold one-on-one meetings with registered attendees, and a live webcast will be available via the company's Investor Relations Events & Presentations page. The company focuses on developing therapies for rare diseases.
2025-10-27 07:30:00
Zevra Therapeutics, Inc. announced it will report its corporate and financial results for the third quarter of 2025 on Wednesday, November 5, 2025, after the market close. The company will also host a conference call and audio webcast at 4:30 p.m. ET on the same day to discuss the results. Details on how to access the webcast and dial into the conference call, including replay information, are provided in the announcement.
2025-10-18 01:20:41
Cantor Fitzgerald has reiterated an Overweight rating and $29.00 price target for Zevra Therapeutics (NASDAQ: ZVRA), citing potential intellectual property developments and strong revenue growth. The firm highlights Zevra's ongoing discussions with the FDA regarding patent term extension and exploration of additional patents. Despite a recent EPS miss, the company's revenue surpassed expectations, driven by MIPLYFFA sales.
2025-10-17 12:09:00
Cantor Fitzgerald reiterated an Overweight rating and a $29.00 price target for Zevra Therapeutics (NASDAQ:ZVRA), citing potential intellectual property developments like Patent Term Extension (PTE) that could extend beyond current Orphan Drug Exclusivity. The firm notes that most analysts probably don't account for such extensions and that Zevra has also demonstrated strong revenue growth. This outlook comes despite Zevra's Q2 2025 EPS falling short, though revenue exceeded expectations.
2025-10-15 07:48:00
Zevra Therapeutics Inc. (ZVRA), a commercial-stage company focused on rare diseases, is gaining attention due to recent clinical and commercial progress with its treatment MIPLYFFA for Niemann-Pick Disease Type C, as well as advancements in its broader pipeline. The company maintains a strong financial position with $217.7 million in cash and has seen its stock perform well, making it a stock to watch.
